The information contained in this site is for
healthcare professionals only.
Prolia® (denosumab) helps strengthen cortical AND TrABECULAR bone tissue and significantly reduce fracture risk
Prolia® (denosumab) is an antiresorptive medicine that is used to treat osteoporosis in postmenopausal women and in men at increased risk of osteoporotic fractures.
Prolia® (denosumab) is a first in class therapy for bone loss with a mechanism of action that reduces the loss of bone and maintains bone strength, making fractures less likely to happen in post menopausal women.
The efficacy of Prolia® (denosumab) has been demonstrated to improve bone density and strength and reduce the risk of osteoporotic fractures in both men and postmenopausal women at increased risk of fracture.
Prolia® (denosumab) is a 60 mg injection for osteoporosis administered subcutaneously every six months.
Learn which denosumab side effects to look out for and safety precautions to take in patients with osteoporosis on treatment with Prolia®.
Download relevant resources here.
Osteoporosis may occur in women after menopause. In postmenopausal women with osteoporosis Prolia® significantly reduces the risk of vertebral, non-vertebral and hip fractures.
Osteoporosis in men may be due to aging, low level of the male hormone, testosterone or hormone ablation therapy. In men with prostate cancer receiving hormone ablation, Prolia® (denosumab) significantly reduces the risk of vertebral fractures.